Tesamorelin — 10mg
Research-grade Tesamorelin, a stabilized 44-amino-acid synthetic analog of human growth hormone-releasing hormone (GHRH) with an N-terminal trans-3-hexenoic acid modification. Studied for sustained pulsatile GH secretion, visceral fat metabolism, and IGF-1 axis research. 10mg lyophilized powder, 99%+ purity verified by Janoshik Analytical via HPLC and mass spectrometry.
For laboratory research use only.
Not for human or veterinary use.
Not intended for diagnosis, treatment, cure, or prevention of any disease.
Use only in controlled laboratory settings by qualified personnel following appropriate safety procedures.
Tesamorelin is a synthetic 44-amino-acid polypeptide analog of human growth hormone-releasing hormone (GHRH), originally developed by Theratechnologies Inc. of Canada. Its distinguishing feature is a trans-3-hexenoic acid group attached to the N-terminal tyrosine residue, which protects against DPP-IV enzymatic cleavage — the primary degradation pathway for native GHRH. Unlike CJC-1295 (No DAC) which modifies internal amino acids, Tesamorelin preserves the complete native GHRH sequence while adding a protective group. It has been the subject of extensive clinical research, including Phase 3 trials and regulatory review.
BENEFITS
GHRH receptor activation — studied as a full-length GHRH analog with enhanced enzymatic stability
Sustained GH pulsatility — investigated for physiological growth hormone release patterns
Visceral fat metabolism — explored in clinical research for effects on regional adipose distribution
IGF-1 axis research — studied for downstream effects on insulin-like growth factor production
Clinical-grade data — one of the most extensively studied GHRH analogs in published literature
WHAT RESEARCHERS LOOK AT
GH/IGF-1 axis stimulation and pulsatile GH release kinetics
Visceral adipose tissue metabolism in clinical and preclinical models
Lipid metabolism pathways and hepatic fat fraction changes
Comparative pharmacokinetics vs. native GHRH (1-44) and sermorelin
N-terminal acylation as a strategy for peptide stabilization
